- Home
- CNNE vs CLDX Comparison
CNNE vs CLDX Comparison
Compare CNNE & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNNE
- CLDX
- Stock Information
- Founded
- CNNE 2014
- CLDX N/A
- Country
- CNNE United States
- CLDX United States
- Employees
- CNNE N/A
- CLDX N/A
- Industry
- CNNE Restaurants
- CLDX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CNNE Consumer Discretionary
- CLDX Health Care
- Exchange
- CNNE Nasdaq
- CLDX Nasdaq
- Market Cap
- CNNE 1.1B
- CLDX 1.2B
- IPO Year
- CNNE N/A
- CLDX 2008
- Fundamental
- Price
- CNNE $17.31
- CLDX $18.30
- Analyst Decision
- CNNE Buy
- CLDX Buy
- Analyst Count
- CNNE 2
- CLDX 8
- Target Price
- CNNE $22.50
- CLDX $54.29
- AVG Volume (30 Days)
- CNNE 841.5K
- CLDX 935.8K
- Earning Date
- CNNE 05-08-2025
- CLDX 05-05-2025
- Dividend Yield
- CNNE 2.77%
- CLDX N/A
- EPS Growth
- CNNE N/A
- CLDX N/A
- EPS
- CNNE N/A
- CLDX N/A
- Revenue
- CNNE $452,500,000.00
- CLDX $7,020,000.00
- Revenue This Year
- CNNE N/A
- CLDX N/A
- Revenue Next Year
- CNNE $2.23
- CLDX N/A
- P/E Ratio
- CNNE N/A
- CLDX N/A
- Revenue Growth
- CNNE N/A
- CLDX 1.99
- 52 Week Low
- CNNE $15.92
- CLDX $14.40
- 52 Week High
- CNNE $22.36
- CLDX $47.00
- Technical
- Relative Strength Index (RSI)
- CNNE 46.44
- CLDX 49.59
- Support Level
- CNNE $17.14
- CLDX $17.45
- Resistance Level
- CNNE $17.82
- CLDX $18.53
- Average True Range (ATR)
- CNNE 0.70
- CLDX 1.37
- MACD
- CNNE 0.01
- CLDX 0.29
- Stochastic Oscillator
- CNNE 44.64
- CLDX 71.69
About CNNE Cannae Holdings Inc.
Cannae Holdings Inc is a holding company that manages and operates a group of companies and investments. The company's reportable segments are Restaurant Group, Dun & Bradstreet, Alight, BKFC, Corporate and Other. Majority of the company's revenue is generated from its Restaurant Group segment which represents the operations of O'Charley's and Ninety Nine Restaurants.
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.